Imatinib Increases Serum Creatinine by Inhibiting Its Tubular Secretion in a Reversible Fashion in Chronic Myeloid Leukemia.

Journal: Clinical lymphoma, myeloma & leukemia
PMID: 26795084

Abstract

BACKGROUND: Monitoring renal function is important in imatinib-treated patients with chronic myeloid leukemia because serum creatinine may increase during the course of therapy. The mechanism of this increase and its reversibility on treatment cessation have never been investigated.

Authors

  • Emmanuelle Vidal-Petiot
    Department of Renal Physiology, DHU Fire, Bichat Hospital, AP-HP, Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Paris, France; INSERM, U1149, Centre de Recherche sur l'Inflammation, Paris, France.
  • Delphine Rea
    Université Paris Diderot, Sorbonne Paris Cité, Paris, France; Department of Adult Hematology, Saint-Louis Hospital, AP-HP, Paris, France.
  • Fidéline Serrano
    Department of Renal Physiology, DHU Fire, Bichat Hospital, AP-HP, Paris, France.
  • Thomas Stehlé
    Department of Renal Physiology, DHU Fire, Bichat Hospital, AP-HP, Paris, France.
  • Claude Gardin
    Department of Hematology, Avicenne Hospital, AP-HP, Bobigny, France.
  • Philippe Rousselot
    Department of Oncology and Hematology, Hôpital André Mignot, Le Chesnay, France.
  • Marie-Noëlle Peraldi
    Université Paris Diderot, Sorbonne Paris Cité, Paris, France; Department of Nephrology, Saint-Louis Hospital, AP-HP, Paris, France.
  • Martin Flamant
    Department of Renal Physiology, DHU Fire, Bichat Hospital, AP-HP, Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Paris, France; INSERM, U1149, Centre de Recherche sur l'Inflammation, Paris, France. Electronic address: martin.flamant@aphp.fr.

Keywords

External Resources

Popular Topics
Recent Journals